Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Yuichi J. Shimada, Jonathan J. Passeri, Aaron L. Baggish, Caitlin O'Callaghan, Patricia A. Lowry, Gia Yannekis, Suhny Abbara, Brian B. Ghoshhajra, Richard D. Rothman, Carolyn Y. Ho, James L. Januzzi, Christine E. Seidman, Michael A. Fifer

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objectives: The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM). Background: Despite evidence that myocardial hypertrophy and fibrosis are mediated by angiotensin II and are important determinants of morbidity and mortality in patients with HCM, no prior studies have evaluated the effects of angiotensin receptor blockers on LV hypertrophy and fibrosis with cardiac magnetic resonance imaging. Methods: In double-blind fashion, 20 patients (3 women, 17 men; age: 51 ± 13 years) with HCM were randomly assigned to receive placebo (n= 9) or losartan 50 mg twice a day (n= 11) for 1 year. Cardiac magnetic resonance imaging was performed at baseline and 1 year to measure LV mass and extent of fibrosis as assessed by late gadolinium enhancement. Results: There was a trend toward a significant difference in the percent change in LV mass (median [interquartile range]:+5% [-4% to+21%] with placebo vs.-5% [-11% to-0.9%] with losartan; p= 0.06). There was a significant difference in the percent change in extent of late gadolinium enhancement, with the placebo group experiencing a larger increase (+31% ± 26% with placebo vs.-23% ± 45% with losartan; p= 0.03). Conclusions: This pilot study suggests attenuation of progression of myocardial hypertrophy and fibrosis with losartan in patients with nonobstructive HCM. Confirmation of these results in a larger trial is required to confirm a place for angiotensin receptor blockers in the management of patients with HCM. (Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy; NCT01150461).

Original languageEnglish (US)
Pages (from-to)480-487
Number of pages8
JournalJACC: Heart Failure
Volume1
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Losartan
Hypertrophic Cardiomyopathy
Left Ventricular Hypertrophy
Fibrosis
Placebos
Angiotensin Receptor Antagonists
Gadolinium
Hypertrophy
Magnetic Resonance Imaging
Double-Blind Method
Angiotensin II
Morbidity
Mortality

Keywords

  • Angiotensin II receptor blocker
  • Cardiac magnetic resonance imaging
  • Hypertrophic cardiomyopathy
  • Late gadolinium enhancement
  • Left ventricular fibrosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Shimada, Y. J., Passeri, J. J., Baggish, A. L., O'Callaghan, C., Lowry, P. A., Yannekis, G., ... Fifer, M. A. (2013). Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure, 1(6), 480-487. https://doi.org/10.1016/j.jchf.2013.09.001

Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy. / Shimada, Yuichi J.; Passeri, Jonathan J.; Baggish, Aaron L.; O'Callaghan, Caitlin; Lowry, Patricia A.; Yannekis, Gia; Abbara, Suhny; Ghoshhajra, Brian B.; Rothman, Richard D.; Ho, Carolyn Y.; Januzzi, James L.; Seidman, Christine E.; Fifer, Michael A.

In: JACC: Heart Failure, Vol. 1, No. 6, 12.2013, p. 480-487.

Research output: Contribution to journalArticle

Shimada, YJ, Passeri, JJ, Baggish, AL, O'Callaghan, C, Lowry, PA, Yannekis, G, Abbara, S, Ghoshhajra, BB, Rothman, RD, Ho, CY, Januzzi, JL, Seidman, CE & Fifer, MA 2013, 'Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy', JACC: Heart Failure, vol. 1, no. 6, pp. 480-487. https://doi.org/10.1016/j.jchf.2013.09.001
Shimada, Yuichi J. ; Passeri, Jonathan J. ; Baggish, Aaron L. ; O'Callaghan, Caitlin ; Lowry, Patricia A. ; Yannekis, Gia ; Abbara, Suhny ; Ghoshhajra, Brian B. ; Rothman, Richard D. ; Ho, Carolyn Y. ; Januzzi, James L. ; Seidman, Christine E. ; Fifer, Michael A. / Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy. In: JACC: Heart Failure. 2013 ; Vol. 1, No. 6. pp. 480-487.
@article{73703460c7fb4f31bf63b89dd4f25dc3,
title = "Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy",
abstract = "Objectives: The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM). Background: Despite evidence that myocardial hypertrophy and fibrosis are mediated by angiotensin II and are important determinants of morbidity and mortality in patients with HCM, no prior studies have evaluated the effects of angiotensin receptor blockers on LV hypertrophy and fibrosis with cardiac magnetic resonance imaging. Methods: In double-blind fashion, 20 patients (3 women, 17 men; age: 51 ± 13 years) with HCM were randomly assigned to receive placebo (n= 9) or losartan 50 mg twice a day (n= 11) for 1 year. Cardiac magnetic resonance imaging was performed at baseline and 1 year to measure LV mass and extent of fibrosis as assessed by late gadolinium enhancement. Results: There was a trend toward a significant difference in the percent change in LV mass (median [interquartile range]:+5{\%} [-4{\%} to+21{\%}] with placebo vs.-5{\%} [-11{\%} to-0.9{\%}] with losartan; p= 0.06). There was a significant difference in the percent change in extent of late gadolinium enhancement, with the placebo group experiencing a larger increase (+31{\%} ± 26{\%} with placebo vs.-23{\%} ± 45{\%} with losartan; p= 0.03). Conclusions: This pilot study suggests attenuation of progression of myocardial hypertrophy and fibrosis with losartan in patients with nonobstructive HCM. Confirmation of these results in a larger trial is required to confirm a place for angiotensin receptor blockers in the management of patients with HCM. (Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy; NCT01150461).",
keywords = "Angiotensin II receptor blocker, Cardiac magnetic resonance imaging, Hypertrophic cardiomyopathy, Late gadolinium enhancement, Left ventricular fibrosis",
author = "Shimada, {Yuichi J.} and Passeri, {Jonathan J.} and Baggish, {Aaron L.} and Caitlin O'Callaghan and Lowry, {Patricia A.} and Gia Yannekis and Suhny Abbara and Ghoshhajra, {Brian B.} and Rothman, {Richard D.} and Ho, {Carolyn Y.} and Januzzi, {James L.} and Seidman, {Christine E.} and Fifer, {Michael A.}",
year = "2013",
month = "12",
doi = "10.1016/j.jchf.2013.09.001",
language = "English (US)",
volume = "1",
pages = "480--487",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy

AU - Shimada, Yuichi J.

AU - Passeri, Jonathan J.

AU - Baggish, Aaron L.

AU - O'Callaghan, Caitlin

AU - Lowry, Patricia A.

AU - Yannekis, Gia

AU - Abbara, Suhny

AU - Ghoshhajra, Brian B.

AU - Rothman, Richard D.

AU - Ho, Carolyn Y.

AU - Januzzi, James L.

AU - Seidman, Christine E.

AU - Fifer, Michael A.

PY - 2013/12

Y1 - 2013/12

N2 - Objectives: The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM). Background: Despite evidence that myocardial hypertrophy and fibrosis are mediated by angiotensin II and are important determinants of morbidity and mortality in patients with HCM, no prior studies have evaluated the effects of angiotensin receptor blockers on LV hypertrophy and fibrosis with cardiac magnetic resonance imaging. Methods: In double-blind fashion, 20 patients (3 women, 17 men; age: 51 ± 13 years) with HCM were randomly assigned to receive placebo (n= 9) or losartan 50 mg twice a day (n= 11) for 1 year. Cardiac magnetic resonance imaging was performed at baseline and 1 year to measure LV mass and extent of fibrosis as assessed by late gadolinium enhancement. Results: There was a trend toward a significant difference in the percent change in LV mass (median [interquartile range]:+5% [-4% to+21%] with placebo vs.-5% [-11% to-0.9%] with losartan; p= 0.06). There was a significant difference in the percent change in extent of late gadolinium enhancement, with the placebo group experiencing a larger increase (+31% ± 26% with placebo vs.-23% ± 45% with losartan; p= 0.03). Conclusions: This pilot study suggests attenuation of progression of myocardial hypertrophy and fibrosis with losartan in patients with nonobstructive HCM. Confirmation of these results in a larger trial is required to confirm a place for angiotensin receptor blockers in the management of patients with HCM. (Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy; NCT01150461).

AB - Objectives: The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM). Background: Despite evidence that myocardial hypertrophy and fibrosis are mediated by angiotensin II and are important determinants of morbidity and mortality in patients with HCM, no prior studies have evaluated the effects of angiotensin receptor blockers on LV hypertrophy and fibrosis with cardiac magnetic resonance imaging. Methods: In double-blind fashion, 20 patients (3 women, 17 men; age: 51 ± 13 years) with HCM were randomly assigned to receive placebo (n= 9) or losartan 50 mg twice a day (n= 11) for 1 year. Cardiac magnetic resonance imaging was performed at baseline and 1 year to measure LV mass and extent of fibrosis as assessed by late gadolinium enhancement. Results: There was a trend toward a significant difference in the percent change in LV mass (median [interquartile range]:+5% [-4% to+21%] with placebo vs.-5% [-11% to-0.9%] with losartan; p= 0.06). There was a significant difference in the percent change in extent of late gadolinium enhancement, with the placebo group experiencing a larger increase (+31% ± 26% with placebo vs.-23% ± 45% with losartan; p= 0.03). Conclusions: This pilot study suggests attenuation of progression of myocardial hypertrophy and fibrosis with losartan in patients with nonobstructive HCM. Confirmation of these results in a larger trial is required to confirm a place for angiotensin receptor blockers in the management of patients with HCM. (Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy; NCT01150461).

KW - Angiotensin II receptor blocker

KW - Cardiac magnetic resonance imaging

KW - Hypertrophic cardiomyopathy

KW - Late gadolinium enhancement

KW - Left ventricular fibrosis

UR - http://www.scopus.com/inward/record.url?scp=84889091885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889091885&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2013.09.001

DO - 10.1016/j.jchf.2013.09.001

M3 - Article

VL - 1

SP - 480

EP - 487

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 6

ER -